

Rectiv® (nitroglycerin) - First-time generic

- On February 23, 2024, <u>Cosette launched</u> an <u>AB-rated</u> generic version of AbbVie's <u>Rectiv</u> (nitroglycerin) 0.4% rectal ointment.
 - Cosette was granted 180 days of Competitive Generic Therapy exclusivity.
- Rectiv is approved for the treatment of moderate to severe pain associated with chronic anal fissure.
- Nitroglycerin is available generically in a variety of formulations such as injection, oral, and transdermal. These are all used for different indications than Rectiv.
- According to IQVIA, Rectiv had estimated annual sales in the U.S. of \$21.2 million as of January 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.